In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations.

Abstract

The tremendous evolution of genome-editing tools in the last two decades has provided innovative and effective approaches for gene therapy of congenital and acquired diseases. Zinc-finger nucleases (ZFNs), transcription activator- like effector nucleases (TALENs) and CRISPR-Cas9 have been already applied by ex vivo hematopoietic stem cell (HSC) gene therapy in genetic diseases (i.e., Hemoglobinopathies, Fanconi anemia and hereditary Immunodeficiencies) as well as infectious diseases (i.e., HIV), and the recent development of CRISPR-Cas9-based systems using base and prime editors as well as epigenome editors has provided safer tools for gene therapy. The ex vivo approach for gene addition or editing of HSCs, however, is complex, invasive, technically challenging, costly and not free of toxicity. In vivo gene addition or editing promise to transform gene therapy from a highly sophisticated strategy to a "user-friendly' approach to eventually become a broadly available, highly accessible and potentially affordable treatment modality. In the present review article, based on the lessons gained by more than 3 decades of ex vivo HSC gene therapy, we discuss the concept, the tools, the progress made and the challenges to clinical translation of in vivo HSC gene editing.

• Authors: Nikoletta Psatha, Kiriaki Paschoudi, Anastasia Papadopoulou, Evangelia Yannaki
• Journal: Genes (Genes (Basel)) Vol. 13 Issue 12 (11 27 2022) ISSN: 2073-4425 [Electronic] Switzerland
• PMID: 36553489 (Publication Type: Journal Article, Review)

Chemical References

• Transcription Activator-Like Effector Nucleases

Topics

• Gene Editing
• CRISPR-Cas Systems (genetics)
• Hematopoietic Stem Cells
• Genetic Therapy
• Transcription Activator-Like Effector Nucleases